Drug Profile
Edodekin alfa
Alternative Names: CLMF; human interleukin-12; NKSF; Recombinant human interleukin-12; rhIL-12; rHuIL-12; RO 247472; YM 01CLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Roche; Wistar Institute
- Developer Bausch Health Companies; Roche
- Class Adjuvants; Immunotherapies; Interleukins
- Mechanism of Action Angiogenesis inhibitors; Cytokine stimulants; Immunostimulants; Interferon gamma stimulants; Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Bacterial infections; Cancer; Cutaneous T-cell lymphoma; Graft-versus-host disease; Hepatitis B; Hepatitis C; HIV infections; Kaposi's sarcoma; Leishmaniasis; Lymphoma; Malaria; Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (Inhalation)
- 04 Sep 2006 Discontinued - Phase-I for Asthma in USA (SC)